Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Men with Early-Stage Prostate Cancer Could Delay Treatment In Favour Of Disease Monitoring

XTALKS VITALS NEWS

Prostate Cancer

Active surveillance uses regular physical exams, blood tests and biopsies to determine whether a prostate tumor is progressing before treatment options are considered.

Share this!

October 25, 2016 | by Sarah Hand, M.Sc.

A new report found that over half of the 32,518 Swedish men diagnosed with prostate cancer over a five-year period, chose to monitor their disease as opposed to opting for radiation therapy or surgery. The study – which was published in the journal, JAMA Oncology – suggests that active monitoring could be a safe choice for American prostate cancer patients as well.

Active surveillance uses regular physical exams, blood tests and biopsies to determine whether a prostate tumor is progressing before treatment options are considered. According to the researchers, low-risk patients can avoid treatment-associated side effects – including bowel and bladder incontinence as well as sexual dysfunction – by deciding to actively monitor their disease.

“The main conclusion here is that if the majority of men in Sweden have adopted this management strategy for very low- to low-risk prostate cancer, then more American men might choose this option if it were presented to them,” said lead study author Dr. Stacy Loeb, a urologist at NYU Langone Medical Center. Loeb and her colleagues collaborated with an international team of researchers to complete the study.



Between 2009 and 2014, the researchers found that the incidence of active surveillance among Swedish men diagnosed with very low-risk prostate cancer increased, from 57 to 91 percent. Similarly, in 2014, 74 percent of men with low-risk cancer chose this option, which was up from 40 percent in 2009.

What’s more, the percentage of men who chose the most passive option called watchful waiting, whereby patients forgo further testing and treatment until symptoms develop, decreased by over 50 percent. To complete the study, the researchers used data from Sweden's National Prostate Cancer Register, a unique database with no current US equivalent.

“Our findings should encourage physicians and cancer care professionals in the United States to offer such close supervision and monitoring to their patients with low-risk disease,” said Loeb. “[Increased adoption of active surveillance] could go a long way toward reducing the harms of screening by minimizing overtreatment of non-aggressive prostate cancer.”

A recent study also showed no difference in mortality between men who chose active surveillance and those that chose treatment. According to Loeb, some men who chose to treat their early-stage prostate cancer have later regretted their decision because of long-lasting side effects.


Keywords: Prostate Cancer, Blood Test, Biopsy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.